cyrilzakka/clinical-trials huggingface dataset:
Neuroplasticity: The Effects of Exercise Training on Cognitive and Affective Functioning of Older People

This study investigates the effects of exercise on older people's cognitive and affective functions, and the possible underlying neurobiological pathways.

Population aging is accelerating. The socioeconomic burden associated with an aging population calls for timely action for promoting brain health. The human brain has the capacity for plastic reorganization through learning and experience. Physical activity could induce plasticity and is important in the prevention of functional decline and increased survival. In this study, the effects of Qigong and stretching exercise on affective and cognitive function among the healthy elderly are investigated. This study is proposed to invite 200 participants (100 in each intervention condition). The investigators acquire data from questionnaires, assessments, neurocognitive tests, magnetic resonance imaging and blood samples at baseline (before the intervention) and post-intervention.

Eligibility Criteria:
Inclusion Criteria:

1. At least finished primary school;
2. Have normal or corrected-to-normal vision and hearing;
3. Ability to do exercise;
4. Right-hand dominance;
5. Normal cognitive ability as assessed by the Montreal Cognitive Assessment Hong Kong version (HK-MoCA).

Exclusion Criteria:

1. Abmormal anxiety or depression mood as measured by the Hospital Anxiety and Depression Scale;
2. Current diagnosis or history of neurological or psychological conditions, such as substance abuse, psychotic disorders, or affective disorders;
3. Current diagnosis or history of substance/alcohol abuse;
4. Contraindications for MRI scanning (e.g. implanted metal);
5. People who regularly practice any qigong, Tai Chi or similar exercise or meditation within 6 months before study;
6. People who regularly practice moderate to high intensity physical exercise within 6 months before study. The operational definition of 'regular practice' is three times a week or more, at least 30 mins per time for at least 3 months.
A Long Term, Safety Study of Apricitabine in HIV-infected Subjects

The study will examine how safe and effective apricitabine is when given long term (as ongoing treatment) to HIV patients who have already completed the AVX-201 trial

An ongoing study (AVX-201) is examining the safety and efficacy of apricitabine compared to 3TC in HIV patients who are failing therapy containing 3TC and have the presence of the M184V mutation in reverse transcriptase. This extension study (AVX-201E) is available to patients who complete the AVX-201 protocol.

Patients will continue to receive apricitabine open label for a further 96 weeks (making a total of 144 weeks from starting AVX-201) in addition to an optimised background. Safety markers and efficacy markers will be followed.

Eligibility Criteria:
Inclusion Criteria:

* Completed AVX-201 protocol, Plasma HIV RNA \<5000 copies/ml, CD4 cells \>50

Exclusion Criteria:

* Pregnant or breastfeeding females, withdrawal from AVX-201
Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)

The main aim is to study in the real world setting the effectiveness of Cladribine tablets in terms of Annualized Relapse Rate (ARR) and disability progression, in participants who switched from a first line Disease Modifying Drug (DMD) (Interferons, Glatiramer Acetate, Teriflunomide, (Dymethyl fumarate) \[DMF\]) to treatment with Cladribine tablets in routine clinical practice.


Eligibility Criteria:
Inclusion Criteria:

* Participants with confirmed diagnosis of RRMS diagnosed by the treating physician according to applicable clinical practice guidelines -(currently McDonald 2017 criteria), with high disease activity
* Participants should have been treated with the same first-line DMD (Interferons, Glatiramer Acetate, Teriflunomide, DMF) and at a stable dose for at least one year prior to switch to Cladribine tablets and should have been prescribed Cladribine tablets, according to the decision of the treating physician, prior to enrollment in the study. Any washout period and/or washout methods required before switching (such as elimination of Teriflunomide) must have been conducted, according to the decision of the treating physician
* Required history data should be available: Multiple Sclerosis (MS) data for the 12-months pre-baseline period (annualized relapse rate); MS Medication History (prior DMDs)
* Fulfilment of the criteria for treatment with Cladribine tablets per standard of care in accordance with the local Summary of Product Characteristics (SmPC)

Exclusion Criteria:

* Contraindications to use of cladribine tablets according to the SmPC
* Participants with history of alcohol or drug abuse that could potentially interfere with their participation in the study
* Participants that have received Cladribine in the past
* Concurrent participation in an investigational study in which participant assessment and/or treatment may be dictated by a protocol
Clinical Study on Optimised Removal of Protein-bound Uremic Toxins With Convective Dialysis Treatment.

Patients will be treated with hemodiafiltration (HDF) in postdilution mode, as a control therapy, during 9 weeks. During week 5 the 1st intervention treatment, predilution hemofiltration (HF) or predilution HDF, will be performed as a midweek session. After 4 additional weeks of control therapy the other intervention treatment will be performed. Samples will be taken during week 4, 5 and 9: from inlet blood flow (0, 30, 60, 120 and 240 min), from outlet blood flow and dialysate outflow (30, 60, 120 and 240 min).


Eligibility Criteria:
Inclusion Criteria:

* stable on hemodialysis \>= 6 months
* of which presently on high-flux HD \>= 1 month
* 18 years \< age \< 85 years
* blood flow rate \>= 300ml/min

Exclusion Criteria:

* expected survival \< 1 year
* expected transplant within \< 1 year
* infectious diseases
* pregnancy
* chronic inflammation condition
* treated with single needle dialysis
* presently treated with hemodiafiltration or low-flux hemodiafiltration
* expected intradialytic body weight gain \>= 4kg
Effect of T-scan Occlusal Analysis and Adjustment vs Articulating

The aim of this study is to compare two different methods for occlusal analysis of implant - supported prosthesis (T-scan and conventional method with articulating papers) regarding the stresses transmitted to the implants.

Four implants will be inserted, two implants in canine regions and two implants in lower second premolar regions.

After 3 months, two identical overdentures will be constructed for the patient on implants.

The occlusion of each one of the two identical prostheses will be adjusted intraorally but according to different occlusal analysis:

* Group (A) : occlusal adjustments for the overdenture will be done according to articulating paper analysis.
* Group (B) :- occlusal adjustments for the overdenture will be done according to T-scan analysis.

The two prostheses will be retained on dummy implants on acrylic cast and will be loaded under chewing simulator.

The strain developed around the dummy implants will be measured. The data will be recorded manually then will be transferred into digital form. The obtained data will be recorded, tabulated and statistically analyzed using the appropriate tests for comparison within each group.

Eligibility Criteria:
Inclusion Criteria:

* Age range from 55-65.
* Radiographic examination should reveal bone height more than 10 mm and crestal bone width not less than 5 mm of the inter-foraminal region.
* Residual bone and mucosa should be free from any pathological signs, bony undercuts, or neoplasia.
* Adequate salivary flow.
* Adequate mouth opening.
* Adequate inter-arch space.

Exclusion Criteria:

* Systemic diseases affecting metabolism of bone e.g uncontrolled diabetes, bone diseases, hyperparathyroidism and renal disease.
* Severe blood diseases (hemophilia etc.).
* Severe vascular heart disease.
* Liver Problems.
* Cerebral infarction .
* Severe immunodeficiency.
* Patients who are undergoing strong chemotherapy.
* Excessive alcohol consumption.
* Severe neuropsychiatric disease, mental disability, and narcotic drug addict
* Uncooperative patients
Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence

This study is designed to evaluate the safety, tolerability and preliminary efficacy of vernakalant (oral) in subjects with sustained atrial fibrillation of greater than 72 hours and less than 6 months duration


Eligibility Criteria:
Inclusion Criteria (partial list):

* Subjects must have sustained, symptomatic atrial fibrillation for greater than 72 hours and less than 6 months duration
* Subjects must have adequate anticoagulant therapy

Exclusion Criteria (partial list):

* Subjects may not have Class III or Class IV congestive heart failure
* Subjects may not have uncorrected electrolyte imbalance
Influence of Escitalopram on Fear Conditioning

The purpose of the study is to learn how differences in learning under mildly-stressful circumstances may be changed by taking an antidepressant medication. This medication is called Lexapro (Escitalopram). The investigators will also examine the impact of any anxiety, depression, and stress related symptoms on learning processes. The investigators will also look at the response of these symptoms to Lexapro.


Eligibility Criteria:
Inclusion Criteria:

1. Male or female outpatients 18 to 75 years of age
2. Must have no current DSM-IV Axis I diagnosis as measured by the SCID (Structured Clinical Interview for DSM-IV-TR axis 1 disorders) with a trained study investigator. Past history of anxiety disorders, major depressive episodes or substance abuse disorders at least six months prior to baseline are not exclusionary.

Exclusion Criteria:

1. Patients will be excluded from entry into the study for current serious medical conditions or other conditions deemed likely to result in surgery or hospitalization.
2. Patients with a history of trauma resulting in head injury related seizures, or with epilepsy (except a prior history of febrile seizures of infancy which are not exclusionary).
3. Pregnant or lactating women or those of childbearing potential not using medically accepted forms of contraception will be excluded.
4. Concurrent use of other antidepressants, benzodiazepines or antipsychotic medications.
5. Patients with a history of hypersensitivity to escitalopram are excluded.
6. Individuals must have discontinued MAO inhibitors more than 14 days before starting study drug.
7. Additional contraindicated drugs during the study are pimozide, furazolidine, isocarboxazid, lazabemide, and St. John's Wort.
8. Participants meeting DSM-IV or SCID criteria for a substance use disorder in the last six months other than nicotine dependence and those with a positive toxicology screen at baseline consistent with evidence of current substance abuse or dependence as determined by clinical interview.
9. A lifetime history of Bipolar or any psychotic disorder is excluded.
10. Current claustrophobia is exclusionary.
11. Patients currently taking any narcotic will be excluded.
Concurrent Nimotuzumab Versus Cisplatin With Radiotherapy for Locoregionally Advanced NPC

The study is to evaluate whether concurrent nimotuzumab could decrease the severe acute treatment-related toxicities compared with concurrent chemoradiotherapy for locoregionally advanced NPC. Three hundreds and twenty patients will be recruited into this study.

Scheme:

Eligible stage III and IVA/B NPC patients will first be stratified by institution, then randomized to 2 arms at 1:1 ratio.

- Arm Cisplatin:

Neoadjuvant TPF chemotherapy (docetaxel 75 mg/m2, cisplatin 75 mg/m2, 5-FU 2500 mg/m2 every 3 weeks for 3 cycles), followed by cisplatin 40 mg/m2/week in concurrent with IMRT

- Arm nimotuzumab:

Neoadjuvant TPF chemotherapy (docetaxel 75 mg/m2, cisplatin 75 mg/m2, 5-FU 2500 mg/m2 every 3 weeks for 3 cycles), followed by weekly nimotuzumab 200mg in concurrent with IMRT

Eligibility Criteria:
Inclusion Criteria:

* Histologically proven poorly differentiated or undifferentiated carcinoma of the nasopharynx.
* Stage III and IVA/B NPC patients
* KPS \>70
* Age between 18-70
* AGC \> 2000, platelets \> 100,000, AST or ALT\<2 x upper normal, serum creatinine\<1.5mg/dl, creatinine clearance \>50ml/min

Exclusion Criteria:

* Histology other than poorly differentiated or undifferentiated carcinoma, including keratinized squamous cell carcinoma.
* Evidence of metastases (below the clavicle or distant) by clinical or radiographic examinations.
* Initial surgical treatment excluding diagnostic biopsy of the primary site or neck disease.
* Patients with simultaneous or prior malignancy (not include basal cell carcinoma of skin)
* Prior radiation treatment to the head and neck or any prior chemotherapy
Targeted Translocator Protein PET Imaging Evaluate Neuroinflammation of the Chronic Pain Patients

Chronic pain is a major public health issue, which seriously affects patients' quality of life. Neuroinflammation is an important mechanism resulting in chronic pain. Translocator protein (TSPO) has served as a marker of microglial activation and neuroinflammation. 18F-DPA714, a tracer targeted TSPO, can be used to evaluate the microglial activation and neuroinflammation in vivo by PET imaging.Recent and increasing studies have found changes in TSPO and its ligands in various chronic pain models. Reversing their expressions has been shown to alleviate chronic pain in these models, illustrating the effects of TSPO and its ligands.The investigators aim to explore the clinical feasibility used 18F-DPA714 PET imaging to monitor microglial cells activation of center nervous system in chronic pain patients. This study might reveal significant neuroinflammatory process in the center nervous system of the chronic pain patients. The results of this study might provide a new biomarker of disease pathological progression and indicates that TSPO-based therapy may become an alternative strategy for treating chronic pain.


Eligibility Criteria:
Inclusion Criteria:

* chronic pain patients
* Written informed consent was provided by the patients and their family

Exclusion Criteria:

* history of head trauma ， epilepsy， claustrophobia, rheumatic or autoimmune diseases, psychiatric disorders, severe somatic diseases (neurological,cardiovascular, etc.),previous heart or brain surgery, substance abuse, inability to refrain from hypnotics, magnetic implants, pregnancy, lactation
Analysis of RV-Dysfunction in Fallot Patients

In the presented study TDI will be used as a modern technique to characterize RV-function in Fallot patients at rest and during different exercise conditions.

Tissue Doppler imaging (TDI) presents a modern technique to depict the velocity of tissue motion within a distinct area of the myocardium providing amendatory characterization of diastolic and systolic function of the heart. TDI is hypothesized to be of additional value in the evaluation of adult congenital heart disease, especially tetralogy of Fallot (TOF), which is one of the most common conditions. In particular, Fallot patients are at risk of developing right ventricular (RV) dysfunction due to pulmonary valve defects or alterations of the outflow tract. It is pivotal to recognize this progression at an early stage before irreversible changes occur. Aim of the study is to test feasibility of TDI in Fallot patients as a new technique that provides new parameters to characterize RV dysfunction, more precise than common methods. Additionally TDI is performed at rest and during different endurance testings (passive Leg Raising (PLR), handgrip (HG) and cardiopulmonary exercise (CPX), as certain changes might be compensated at rest, first apparent during exercise.

Eligibility Criteria:
Inclusion Criteria:

* Patients with corrected tetralogy of Fallot
* Adult healthy controls without cardiovascular disease or other relevant systemic diseases with written consent

Exclusion Criteria:

* Inability to give written consent, incapable of cycling or handgrip exercise due to cognitive or orthopedic limitation, poor echocardiographic image quality
Electronic Triggers: Microhematuria Trigger

The research team will evaluate the effectiveness of an InBasket Results message that prompts providers to place appropriate follow up orders.

The research team will evaluate the effectiveness of an InBasket Results message that prompts providers to place appropriate follow up orders. The message will notify users that a patient has clinically significant microscopic hematuria and is at high risk for underlying malignancy and will include the official recommendations (imaging with a CT urogram, urology evaluation with cystoscopy).

Eligibility Criteria:
Inclusion Criteria:

* 35 years of age or older
* 3+ RBC on Urinalysis
* Urinalysis sent during an outpatient encounter
* any of the following: 60 years of age or older; RBC \> 25; current or prior tobacco use; Gross Hematuria

Exclusion Criteria:

* Under 35 years of age
* Cystoscopy within 1 year prior to Urinalysis
* Nitrite positive AND Leukocyte Esterase positive
* Nitrite positive AND \>100 WBC
* Leukocyte Esterase positive AND \>100 WBC
* Know GU cancer diagnosis
* Urinalysis ordered by urology provider
Components of Social Functioning in Survivors of Pediatric Brain Tumors

Children with brain tumors are at risk for a number of psychological late effects, including neurocognitive and social deficits. This observational study focuses on assessment of social functioning, including social-cognitive and neurocognitive abilities, in survivors of pediatric brain tumors. This study will also assess the influence of medical factors, including diagnosis and age at diagnosis, on social functioning.

PRIMARY OBJECTIVE: Examine the impact of social-cognitive and neurocognitive abilities on social functioning in survivors of pediatric brain tumors.

SECONDARY OBJECTIVE: Assess the influence of medical factors such as diagnosis and age at diagnosis on the social functioning of survivors of pediatric brain tumors.

Assessment of social and neurocognitive functioning in survivors of pediatric brain tumors who are least two years post-therapy and between 8 and 12 years of age will be included. Participants will be recruited from two tumor types: 1) medulloblastoma, and 2) other brain tumors that were not treated with craniospinal irradiation. Upon enrollment, participants will complete standard psychological questionnaires used to evaluate both performance-based and self-report measures of social and neurocognitive functioning. Parents will complete questionnaires. Families will be asked for permission to contact teachers to complete additional questionnaires. Children will identify their best friend as part of their questionnaires and will be asked permission to contact this friend to complete two questionnaires. Finally, children will be asked to complete an online daily diary of social interactions for seven days.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of medulloblastoma or other brain tumor
* Current age between 8 and 12 years, inclusive
* At least 2 years post-completion of therapy
* Enrolled in school full-time
* English speaking
* Cognitive and language capacity to complete measures
* Teacher inclusion: Consent received from survivor and parent to contact.
* Best Friends inclusion: (1) Consent received from survivor and parent to contact, (2) English-speaking, (3) Cognitive capacity to complete questionnaires as judged by the parent during the consent process.

Exclusion Criteria:

* Diagnosis of a genetic disorder/pre-existing neurodevelopmental condition associated with neurocognitive or social impairment (e.g., autism, Neurofibromatosis Type 1 (NF1), Down syndrome
* Homeschooled or full-time special education
* IQ less than 70 as documented in the medical record
* Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.
* Other tumor cohort exclusion: (1) diagnosis of craniopharyngioma, (2) treatment history includes craniospinal irradiation (CSI).
TakeCharge: Telephone Delivered Self-management Intervention for People With Multiple Sclerosis (MS)

The proposed project will evaluate the efficacy of a telephone-delivered self-management (T-SM) intervention for reducing the impact of secondary conditions in persons with multiple sclerosis (MS), including chronic pain, fatigue, depression, and cognitive impairment. It is hypothesized that if the effects of these conditions are reduced, study participants will demonstrate improved participation in the community and improved employment outcomes. This project is important because the majority of persons with MS experience one or more of the following secondary conditions: fatigue, pain, depression, and cognitive impairment. These secondary conditions are not always readily apparent and constitute what has been described by our Rehabilitation Research and Training Center as "hidden disabilities." Secondary conditions such as pain, depression, fatigue, and cognitive impairment frequently not only cause distress in their own right but also affect employment, participation, and quality of life. Having more than one often compounds the effect; the effect of all may be greater than the sum of each individually (e.g. depression can worsen fatigue, and cognitive impairment can worsen depression).

It is critical that this constellation of secondary symptoms be addressed using state of the art techniques based on self-management training and that intervention effects be documented with carefully controlled treatment efficacy studies.


Eligibility Criteria:
Inclusion Criteria:

* Must be diagnosed with MS by a physician.
* Must be at least 18 years of age.
* Must be able to understand, speak, and read English.
* Must have the presence of at least one of four common secondary conditions (fatigue, pain, depression, cognitive difficulties) that interferes with employment, participation, and functioning.

Exclusion Criteria:

* Unable to understand or read English.
* Severe cognitive impairment, defined as one or more errors on the 6-item screener, that would prevent informed consent and inability to carry on a phone conversation.
* Currently participating in regularly scheduled psychotherapy.
* Psychiatric contraindications such as current psychosis, active suicidal ideation, or current alcohol or drug use.